The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Preventing Diabetes In Pregnancy From Progressing To Type 2 Diabetes: Macrolevel System Change In South Australia And Vic
Funder
National Health and Medical Research Council
Funding Amount
$1,338,281.00
Summary
The greatest predictor of the likelihood of developing diabetes is having diabetes during pregnancy. This project will invite women who have developed diabetes during pregnancy to be registered for recall every two years. They would go to their general practitioner to be tested for diabetes and to be advised on risk factors for diabetes. A lifestyle modification program will be developed for these women to reduce the risk of progressing to diabetes.
Should Australia Introduce A National Chlamydia Testing Program? Evaluation Of A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$518,510.00
Summary
Chlamydia is a very common sexually transmissible infection that can lead to infertility in women. About 4% of young adults have it, yet most are unaware they have it. Chlamydia is easy to diagnose and treat, but it is not known whether annual testing can reduce its spread. Over1 million tests are conducted each year in general practice, costing the government $30 million. This evaluation of a well-established trial of chlamydia testing in young adults will resolve the debate of whether annual t ....Chlamydia is a very common sexually transmissible infection that can lead to infertility in women. About 4% of young adults have it, yet most are unaware they have it. Chlamydia is easy to diagnose and treat, but it is not known whether annual testing can reduce its spread. Over1 million tests are conducted each year in general practice, costing the government $30 million. This evaluation of a well-established trial of chlamydia testing in young adults will resolve the debate of whether annual testing works and is a good use of money.Read moreRead less
Improving Maternal And Infant Outcomes: A Multicentre Randomised Controlled Trial Of Midwifery And Dental Intervention
Funder
National Health and Medical Research Council
Funding Amount
$457,724.00
Summary
Poor oral health during pregnancy can impact the health of the mother and baby. Yet, many expectant mothers are unaware of the implications of poor oral health. In Australia there is a lack of importance being placed on maternal oral health. The aim of this study is to determine the effectiveness of a new service which will promote maternal oral health through collaboration between midwives and dentists. We expect the new service will improve women's oral health, uptake of dental services and po ....Poor oral health during pregnancy can impact the health of the mother and baby. Yet, many expectant mothers are unaware of the implications of poor oral health. In Australia there is a lack of importance being placed on maternal oral health. The aim of this study is to determine the effectiveness of a new service which will promote maternal oral health through collaboration between midwives and dentists. We expect the new service will improve women's oral health, uptake of dental services and potentially improve pregnancy outcomes.Read moreRead less
The Forgotten Generation: Understanding Health Trajectories In Aboriginal Adolescents And Youth
Funder
National Health and Medical Research Council
Funding Amount
$2,095,283.00
Summary
This study will establish a cohort of 2250 young Aboriginal and Torres Strait Islander people from urban, rural and remote communities aged 10 to 24 years. The study will provide longitudinal data on the health status and health trajectories of this group of young Australians who experience poorer health outcomes compared with other young Australians. The proposed study will explored the determinants of health status, how these factors change over time and opportunities for prevention.
I am a molecular geneticist with a main research focus in the identification and characterisation of genes and molecular pathways involved in intellectual disability and epilepsy.
The migration of cancer cells (metastasis) is responsible for most cancer deaths. Central to this is dynamic organisation of the actin cytoskeleton _ an internal structure that provides cell shape and enables movement. We have identified a family of small molecules (called miR-200) that regulates this actin cytoskeleton through specifically downregulating various genes. We are investigating the nature of these genes and their role in cell motility _ an underlying pre-requisite of metastasis.
Can Decision Analytic Modelling Promote Clinical Translation Of Personalised Medicine Markers For Oncology Drugs?
Funder
National Health and Medical Research Council
Funding Amount
$69,893.00
Summary
Personalised medicine is an approach that has great potential to improve healthcare. There has been limited success to date, however, in utilising proposed tests in the clinical. It is proposed that use of mathematical models early in the development of personalised medicine tests will allow early understanding of the value that the test will have for patients and society. Such insight will help build a strong case to undertake the research required before personalised medicine can be more widel ....Personalised medicine is an approach that has great potential to improve healthcare. There has been limited success to date, however, in utilising proposed tests in the clinical. It is proposed that use of mathematical models early in the development of personalised medicine tests will allow early understanding of the value that the test will have for patients and society. Such insight will help build a strong case to undertake the research required before personalised medicine can be more widely used to improve treatment for cancer.Read moreRead less
Personalised Medicine Markers Of Anti-EGFR Antibody Therapy In Metastatic Colorectal Cancer: Accelerating Clinical Translation With Collaborative Meta-analyses Based On Individual-participant Data
Funder
National Health and Medical Research Council
Funding Amount
$300,953.00
Summary
When selecting cancer therapy we take into account ‘biomarkers’, biological cancer characteristics that predict treatment success. We will work with an international group, the Advanced Colorectal Cancer Database, to analyse individual patient clinical trial data. We intend to validate biomarkers used to select treatment with cetuximab or panitumumab. Cancer genes called KRAS, NRAS, PTEN, PIK3CA, EREG and BRAF will be examined. Our study will provide best evidence for personalised treatment.
Pushing AR Toward Better Outcomes In Breast And Prostate Cancers
Funder
National Health and Medical Research Council
Funding Amount
$998,754.00
Summary
Breast and prostate cancers kill >6000 Australians each year. These cancers are strikingly similar, both driven by hormone receptors that have ‘gone bad’. Current therapies aim to eradicate the receptors. While often effective, therapeutic resistance is common and results in fatal disease. We aim to develop new, less toxic treatments that switch receptor behaviour from good to bad, without destroying them. This should improve quality of life, while preventing drug resistance and loss of lives ....Breast and prostate cancers kill >6000 Australians each year. These cancers are strikingly similar, both driven by hormone receptors that have ‘gone bad’. Current therapies aim to eradicate the receptors. While often effective, therapeutic resistance is common and results in fatal disease. We aim to develop new, less toxic treatments that switch receptor behaviour from good to bad, without destroying them. This should improve quality of life, while preventing drug resistance and loss of lives.Read moreRead less
Mab Immunotherapies For Myeloid Leukemia Patients With Germline Or Somatic RUNX1 Mutations.
Funder
National Health and Medical Research Council
Funding Amount
$766,995.00
Summary
This proposal presents preliminary evidence and proposes to confirm that 2 cell surface molecules, CD11a (ITGAL) and IL3RA (CD123) are direct (probably repression) targets of RUNX1 in HSCs, and are dysregulated in RUNX1 mutated AML. Monoclonal antibody therapies that target these two surface molecules have already passed different clinical trial phases for different diseases. We plan to show these antibodies are effective in RUNX1 positive AML in preclinical models and then clinical trials.